

Zydus Cadila's Total Income from Operations soars to Rs. 1398 crores in Q4

Ahmedabad, May 10, 2012

For the quarter ended 31st March 2012, Zydus Cadila registered a Total Income from Operations of Rs. 1398 crores, up by 15 % from Rs. 1213 crores in the corresponding period last year on a consolidated basis. Net Profit for the same period is up by 16% y-y to Rs. 178 crores (excluding forex fluctuations).

During the quarter, the group's India formulations business posted sales of Rs. 499 crores up by 38 %. The group launched 40 new products which included 16 line extensions. Of these, 10 were first in India launches.

The group's formulation exports was buoyed by 26% growth in sales in the US market. The group's US subsidiary, Zydus Pharmaceuticals USA Inc., was recently ranked 11th amongst the generic companies in terms of prescriptions. During the quarter, the group entered into an agreement with Microbix Biosystems Inc., a biotechnology company commercializing novel technologies to market the Thrombolytic drug, Urokinase in the North American markets.

During the quarter, the group's wellness business grew by 11% to Rs. 86 crores y-y and the animal healthcare business in India grew by 30% to Rs. 43 crores.

Strengthening its regulatory pipeline, the group filed 7 ANDAs during the quarter taking the cumulative to 148 ANDA filings. The group also filed 4 DMFs during the quarter, taking the cumulative number to 107 DMFs. The company filed 7 additional dossiers for new products in the European markets during the quarter, taking cumulative number of new product dossier filings to 136. In Japan, the group filed 4 new products and received 3 approvals during the quarter.
